Acorda Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Acorda Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 1% to $117,633,000. Profit margin reached -215%. Total operating expenses were $94,850,000.
Profit Margin
| 2014 | 401.48M | 17.67M | 4.4% |
|---|---|---|---|
| 2015 | 492.66M | 11.05M | 2.24% |
| 2016 | 519.60M | -34.61M | -6.66% |
| 2017 | 588.28M | -223.35M | -37.97% |
| 2018 | 471.43M | 33.68M | 7.14% |
| 2019 | 192.40M | -272.96M | -141.87% |
| 2020 | 152.96M | -99.59M | -65.11% |
| 2021 | 129.07M | -103.95M | -80.54% |
| 2022 | 118.56M | -65.91M | -55.59% |
| 2023 | 117.63M | -252.85M | -214.95% |
ACOR Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 117.63M | 118.56M | 129.07M | 152.96M | 192.40M | 471.43M | 588.28M | 519.60M | 492.66M | 401.48M |
Cost of revenue | 46.04M | 30.33M | 40.78M | 33.51M | 34.84M | 99.31M | 135.71M | 108.10M | 92.93M | 80.61M |
Gross profit | 71.58M | 88.23M | 88.28M | 119.45M | 157.55M | 372.12M | 452.57M | 411.49M | 399.72M | 320.86M |
Operating exp. | ||||||||||
Research and development | 5.15M | 5.80M | 10.42M | 23.01M | 60.08M | 106.38M | 166.10M | 203.43M | 149.20M | 73.47M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | -320K | -17.55M | 0 | 0 |
Total operating expenses | 94.85M | 130.27M | 165.58M | 206.35M | 278.56M | 278.63M | 347.40M | 421.32M | 354.83M | 275.28M |
Operating income | -23.26M | -42.03M | -77.29M | -86.89M | 14.54M | 38.48M | -232.81M | -35.98M | 33.99M | 36.39M |
Other income (expenses), net | -272.75M | 6.78M | -31.77M | -1.45M | -288.79M | -73.06M | -19.07M | -32.43M | -14.62M | -8.38M |
Income before tax | -296.02M | -35.24M | -109.07M | -107.66M | -274.24M | 20.42M | -251.88M | -42.26M | 19.36M | 28.00M |
Income tax expense | -43.16M | 30.66M | -5.12M | -8.07M | -1.28M | -13.25M | -28.52M | -6.66M | 8.31M | 10.33M |
Net income | -252.85M | -65.91M | -103.95M | -99.59M | -272.96M | 33.68M | -223.35M | -34.61M | 11.05M | 17.67M |
Earnings per share | ||||||||||
Basic EPS | -203.59 | -66.9 | -195.75 | -246.4 | -689.42 | 85.98 | -582.69 | -91.79 | 31.42 | 51.53 |
Diluted EPS | -203.59 | -66.9 | -195.75 | -246.4 | -689.42 | 85.38 | -583.2 | -91.79 | 30 | 50.4 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |